Clinical Trials
92 trialsStudy of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
DRIVE
Pacific Edge Limited
AVENANCE
Pfizer
MK-4700-001
Merck Sharp & Dohme LLC
LEAP-011
Merck Sharp & Dohme LLC
MAGE-A10į¶ā·ā¹ā¶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Adaptimmune
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Hoffmann-La Roche
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Tempest Therapeutics
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
Incyte Corporation
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Incyte Corporation
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
MacroGenics
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
ALX Oncology Inc.
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
Seagen Inc.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Inovio Pharmaceuticals
STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA
Pacific Edge Limited
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Aprea Therapeutics
Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
AstraZeneca
FORT-2
Bayer
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Bristol-Myers Squibb
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
A Study of E7130 in Participants With Solid Tumors
Eisai Inc.
IMvigor130
Hoffmann-La Roche
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
PureTech
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
Daiichi Sankyo
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
RAPT Therapeutics, Inc.
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
Astellas Pharma Inc
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
EV-201
Astellas Pharma Inc
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Eli Lilly and Company
DUET-3
Xencor, Inc.
JAVELIN Bladder 100
Pfizer
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Ikena Oncology
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
PREVAIL
AstraZeneca
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America, Inc.
A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer
RemeGen Co., Ltd.
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
RemeGen Co., Ltd.
FIDES-02
Basilea Pharmaceutica
A Study of a Personalized Neoantigen Cancer Vaccine
Gritstone bio, Inc.
RANGE
Eli Lilly and Company
Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma
NanOlogy, LLC
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Genome & Company
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
OncoNano Medicine, Inc.
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics